Epithelial-mesenchymal transition (EMT) is thought to contribute to metastasis and chemoresistance in patients with hepatocellular carcinoma (HCC), leading to their poor prognosis. The genes driving EMT in HCC are not yet fully understood, however. Here, we show that mobilization of Sleeping Beauty (SB) transposons in immortalized mouse hepatoblasts induces mesenchymal liver tumors on transplantation to nude mice. These tumors show significant down-regulation of epithelial markers, along with up-regulation of mesenchymal markers and EMT-related transcription factors (EMTTFs). Sequencing of transposon insertion sites from tumors identified 233 candidate cancer genes (CCGs) that were enriched for genes and cellular processes driving EMT. Subsequent trunk driver analysis identified 23 CCGs that are predicted to function early in tumorigenesis and whose mutation or alteration in patients with HCC is correlated with poor patient survival. Validation of the top trunk drivers identified in the screen, including MET (MET proto-oncogene, receptor tyrosine kinase), GRB2-associated binding protein 1 (GAB1), HECT, UBA, and WWE domain containing 1 (HUWE1), lysine-specific demethylase 6A (KDM6A), and protein-tyrosine phosphatase, nonreceptor-type 12 (PTPN12), showed that deregulation of these genes activates an EMT program in human HCC cells that enhances tumor cell migration. Finally, deregulation of these genes in human HCC was found to confer sorafenib resistance through apoptotic tolerance and reduced proliferation, consistent with recent studies showing that EMT contributes to the chemoresistance of tumor cells. Our unique cell-based transposon mutagenesis screen appears to be an excellent resource for discovering genes involved in EMT in human HCC and potentially for identifying new drug targets.
H
CC is the sixth most common cancer and the third-leading cause of cancer-related deaths worldwide (1) . In the United States, the incidence of HCC is increasing, and overall 5-y survival is now <12%, despite recent progress in diagnostic and therapeutic modalities (2) . This high mortality rate is related mainly to a high recurrence rate and associated intrahepatic or extrahepatic metastases (1) . Patients with HCC who develop metastasis are no longer eligible for liver transplantation therapy and have very limited therapeutic options. Currently, sorafenib is the sole systemic antineoplastic agent for HCC described in the National Comprehensive Cancer Network (NCCN) guideline (3); however, its clinical benefit is limited (4) , and alternative effective treatments are needed for these patients.
Epithelial-mesenchymal transition (EMT) is a complex differentiation process whereby epithelial cells lose their identity and acquire mesenchymal characteristics (5) . EMT is observed routinely in developmental processes, but is also believed to play an important role in the migration, invasion, and metastasis of various cancers (6) (7) (8) (9) . It also promotes the generation of cancer stem cells, thereby contributing to tumor recurrence and metastasis (10, 11) . Two recent publications have challenged this dogma for breast and pancreatic cancers and have suggested instead that EMT confers chemoresistance rather than metastatic potential to tumor cells (12, 13) . In the case of HCC, growing evidence suggests that EMT contributes to metastasis and poorer patient prognosis (14) (15) (16) (17) . EMT is also positively correlated with resistance to sorafenib, cisplatin, and doxorubicin (18) (19) (20) . Interestingly, sorafenib has been shown to have an inhibitory effect on the migration of HCC cells through inactivation of the EMT program (21) , which is one of the potential mechanisms of its antineoplastic action in HCC. Collectively, the foregoing studies show that EMT has a significant negative impact on survival in patients with HCC through the induction of metastasis and drug resistance. To understand the mechanism(s) regulating EMT in HCC, it will be important to discover all EMT genes to identify therapeutic targets and improve the high mortality of patients with HCC.
Insertional mutagenesis is a powerful in vivo screening tool for cancer gene discovery. Our laboratory has successfully modeled more than 20 different types of human cancers in mice using Sleeping Beauty (SB) transposon mutagenesis and has identified hundreds of candidate cancer genes (CCGs), which show striking overlaps with genes mutated or deregulated in human cancers (22) (23) (24) . We also have developed in vitro cell-based SB mutagenesis screens that have made it possible to identify genes involved in the malignant transformation of neural stem cells into glioma-initiating Significance Epithelial-mesenchymal transition (EMT) contributes to metastasis and chemoresistance in patients with hepatocellular carcinoma (HCC), but the genes driving EMT are poorly understood. Here, we describe a transposon mutagenesis screen that made it possible to identify 233 candidate cancer genes (CCGs) that are enriched for genes driving EMT in HCC. Twenty-three CCGs are predicted to function early in tumorigenesis, and alterations in these genes are associated with poor HCC patient survival. Validation studies showed that deregulation of the most highly mutated CCGs activates an EMT program that enhances HCC cell migration and also confers sorafenib resistance. Thus, transposon mutagenesis appears to provide an excellent resource for identifying genes regulating EMT in human HCC and for potentially identifying new drug targets for HCC.
cells (25) . This versatility and high relevance to human cancers makes SB an invaluable tool for cancer gene identification in mice.
Here, we report that mobilization of SB transposons in immortalized mouse hepatoblasts induces mesenchymal liver tumors on transplantation into nude mice. Cloning and sequencing of the transposon insertions sites from these tumors enabled us to identify 233 CCGs that are enriched for genes driving EMT in human HCC. Twenty-three of these CCGs are predicted to function early in tumorigenesis, and alterations in these genes are associated with poor survival in patients with HCC. Validation studies showed that deregulation of the most highly mutated CCGs activates an EMT program that enhances HCC cell migration and also confers sorafenib resistance. Thus, this unique cell-based transposon mutagenesis screen appears to be an excellent resource for discovering genes involved in EMT in human HCC and for potentially identifying new drug targets for HCC.
Results

SB Transposition in Immortalized Hepatoblasts Induces Mesenchymal
Tumors Following Transplantation. Immortalized hepatoblast cell lines were generated from WT (C57BL6/J) and SB transposonexpressing (Alb-Cre/+;T2Onc2/+;Rosa26-lsl-SB11/+) mice (22) using the method described by Strick-Marchand et al. (26) . In brief, dissociated E13.5 fetal liver cells were plated in culture, and the cultures were incubated until colonies appeared. Seven of 12 plates from Alb-Cre/+;T2Onc2/+;Rosa26-lsl-SB11/+ mice developed colonies that subsequently gave rise to immortalized hepatoblast lines (referred to as IHBC/SB lines), whereas six lines from 18 plates were established from C57BL6/J mice (referred to as IHBC/WT lines). The immortalization rates for the IHBC/WT and IHBC/SB lines were not significantly different (33.3% vs. 58.3%; P = 0.18, χ 2 test), suggesting that SB mutagenesis played little or no role in immortalization of the IHBC/ SB lines (Fig. S1 ). We subsequently confirmed the mobilization of SB transposons in IHBC/SB lines by excision PCR (Fig. 1A) , providing additional evidence that these lines originate from hepatoblasts, because SB transposase activity is restricted to cells expressing Cre under the albumin promoter.
To further demonstrate that these cell lines are derived from hepatoblasts, we measured the mRNA levels of hepatoblast markers Afp, Dlk1, and Epcam in three IHBC/SB cell lines. Each marker was expressed at high levels in IHBC/SB cells compared with control adult mouse liver ( Fig. 1 B-D) , further confirming these cells are derived from hepatoblasts. A unique property of hepatoblasts is their ability to differentiate into mature hepatocytes. To determine whether IHBC/SB cells can differentiate into hepatocytes, we cultured these cells in hepatocyte differentiation medium containing hepatocyte growth factor (HGF), oncostatin M (OSM), and dexamethazone (Dex) (27) . After 14 d in culture, the expression of mature hepatocyte markers Alb, Apob, Aldob, and Glul was greatly increased (Fig.  1 E-H) , whereas the expression of hepatoblast markers Dlk1 and Epcam was decreased ( Fig. 1 I and J) . Thus, IHBC/SB cells retain their ability to differentiate into hepatocytes.
To determine whether these cell lines are tumorigenic in nude mice, we injected cells from seven IHBC/SB lines and six IHBC/ WT lines into the flanks of nude mice and then monitored the mice for tumor formation. Although none of the IHBC/WT lines generated tumors following transplantation, visible tumors (>5 mm diameter) were obtained from five of the seven IHBC/SB lines between 47 and 80 d after transplantation (Fig. 1K) . Thus, transposon mutagenesis appears to be required for the malignant transformation of IHBC cells. Histological analysis showed that tumors were composed of highly proliferative, spindle-shaped cells with vimentin (Vim) immunopositivity, typical of mesenchymal tumors (Fig. 1 L-N) . However, immunohistochemical analysis also showed that these tumors also expressed the epithelial markers pan-cytokeratin and Epcam, as well as SB transposase ( Fig.  1 O-Q). These findings support the hypothesis that these tumors originate from transposase-active hepatoblasts, but acquire mesenchymal characteristics during their growth in vivo. To confirm these results, we reinjected the five tumorigenic IHBC/SB lines into nude mice and generated a total of 52 tumors. Once again, all of these tumors were spindle-shaped mesenchymal tumors. To determine whether the subcutaneous microenvironment might have provided a selective pressure that led to the generation of mesenchymal tumors, we orthotopically injected IHBC/ SB cells into the livers of nude mice. All 10 tumors that developed in the liver were histologically identical to those that developed in the flank (Fig. S2) . These results indicate that the subcutaneous microenvironment did not provide a selective pressure that resulted in the formation of mesenchymal tumors.
IHBC/SB Tumors Have an Activated EMT Program. The mesenchymal nature of these tumors prompted us to ask whether an EMT program had been activated in tumors. We did this by assaying the mRNA expression of 84 EMT-related genes in five IMBC/SB lines and one IMBC/WT line, four IMBC/SB tumors, and an immortalized mouse hepatocyte cell line (AML12). Hierarchical clustering showed distinct expression differences in the IHBC/SB line-derived and IHBC/SB-derived tumors ( Fig. 2A) , whereas similar expression patterns were observed in the IHBC/SB lines, IHBC/WT lines and AML12 cells. We also individually checked the expression levels of EMT-related genes in the IHBC/SB lines, IHBC/SB-derived tumors, and HCC tumors obtained from SB transposon expressing mice (SB/HCCs) by quantitative PCR (qPCR). SB/HCC tumors are well-differentiated HCCs and thus maintain their epithelial characteristics. Thus, they are different from poorly differentiated HCCs, which often exhibit mesenchymal properties (28). Mesenchymal markers Col1a2, Vim, and fibronectin 1 (Fn1) were markedly elevated in IHBC/SB-derived tumors but not in IHBC/SB lines and well-differentiated SB/ HCC tumors ( Fig. 2 B-D) . We also observed a significant decrease in expression of epithelial markers Cdh1 (cadherin 1, type 1, E-cadherin) in IHBC/SB-derived tumors (Fig. 2E) . Finally, we found significant up-regulation of EMT-TFs, snail family zinc finger 1 (Snai1), twist family BHLH transcription factor 1 (Twist1), zinc finger E-box binding homeobox 1 (Zeb1), and Zeb2 (6) in IHBC/SB-derived tumors (Fig. 2 F-I ). These data indicate that an EMT program has been activated in IHBC/SB-derived tumors.
Identification of CCGs Driving the Development of Mesenchymal
Tumors. To identify CCGs driving mesenchymal tumor development, we PCR-amplified and sequenced the transposon insertion sites from seven IHBC/SB lines and all 52 IHBC/SB-derived tumors. To obtain the maximum number of sequencing reads and avoid PCR bias (29), we used Illumina sequencing and acoustic shearing of tumor DNA (Materials and Methods). Using this modified method, we identified 871,231 and 6,541,525 mapped reads, corresponding to 50,215 and 118,530 nonredundant transposon insertion sites from IHBC/SB lines and IHBC/SBderived tumors, respectively (Datasets S1 and S2). Using the gene-centric common integration site (CIS) calling method (gCIS) (30), we identified 61 CCGs from IHBC/SB lines and 233 CCGs from IHBC/SB-derived tumors (P < 0.05, χ 2 test followed by Bonferroni correction) (Tables S1 and S2). CISs are genomic regions that contain more transposon insertions than predicted by chance and thus are likely to mark the location of CCGs (22) . Only one CCG overlapped between these two datasets ( Fig. 3A) , indicating that tumors have acquired new insertional mutations important for their development during growth in vivo.
To determine whether CCGs identified in tumors are significantly enriched for human cancer genes, we compared our list of CCGs to the list of 570 known human cancer genes in the Cancer Gene Census database (31) , and found that 28 GCCs are human cancer genes (Fig. 3B ), which is a highly significant enrichment (P < 0.0001). These results provide additional evidence that insertional mutations in these CCGs are involved in driving the development of mesenchymal tumors.
Previous studies have suggested that most CCGs identified by SB mutagenesis function during late stages of tumor progression (24) . To identify the subset of CCGs that function early in tumor development, we selected transposon insertion sites represented by ≥100 sequencing reads, arguing that these insertions would be present in the largest number of tumor cells. We then performed gCIS analysis on these insertions and identified 23 CCGs that were mutated in six or more tumors. We refer to these CCGs as trunk drivers (Fig. 3C) . Strikingly, Met (MET proto-oncogene, receptor tyrosine kinase) and its binding partner GRB2-associated binding protein 1 (Gab1) were the first and third most significantly mutated trunk drivers. The Met pathway has various important roles in tumor development, including increased proliferation, migration, invasion, and angiogenesis. It is also an inducer of EMT (32) . Seven of the 23 trunk drivers are known human cancer genes, whereas five-Met, Lpp, Pbx1, lysine-specific demethylase 6A (Kdm6a), and Nf1-are reportedly involved in regulating EMT (32) (33) (34) (35) (36) (37) . Another trunk driver, Rasa1, is a Ras GTPase-activating protein that suppresses oncogenic Ras signaling, another EMT inducer (5). The trunk driver Ltbp1 controls the activity of TGF-β, which is also an EMT inducer (38) .
Although there could be some PCR bias in this trunk driver analysis, these analytical results are certainly in agreement with the hypothesis that transposon mutagenesis plays an important role in activating the EMT program and driving a mesenchymal tumor phenotype in tumors generated from immortalized hepatoblasts. Importantly, examination of the cancer genome atlas (TCGA), which contains the mutation and copy number data for 193 HCC patients, shows that deregulation of the 23 trunk drivers in human HCC is significantly correlated with poor patient survival ( Fig. S3) , suggesting the important role of these trunk drivers in human HCC. Oncogenic Activation of the Met/Gab1 Pathway Induces EMT and
Enhances the Migration of Human HCC Cells. We next sought to confirm that the Met/Gab1 pathway plays an important role in regulating EMT in human HCC. We focused on this pathway because 40 of 52 IHBC/SB-derived tumors (76.9%) contain insertions in either or both Met and Gab1 genes (Fig. 4A ).
Transposon insertions are located in the 5′ end of these genes, before exon 3 or 2 ( Fig. 4 B and C) , respectively, suggesting that they are functioning as oncogenes. Consistent with this, the expression of Met and Gab1 was significantly higher in tumors with insertions in Met or Gab1 compared with IHBC/SB lines (Fig. 4 D and E) .
To determine whether the Met/Gab1 pathway plays an important role in regulating EMT in human HCC cells, we treated three human HCC cell lines with hepatocyte growth factor (HGF), which is the ligand for Met (32) . HGF strongly increased Met phosphorylation and slightly up-regulated Gab1 phosphorylation in human HCC cell lines (Fig. 4F ). HGF treatment decreased the expression of epithelial markers, such as E-cadherin, in all three HCC cell lines (Fig. 4G) . Finally, in vitro scratch assays (39) showed that HGF treatment significantly enhanced the migration of HCC cells in vitro (Fig. 4 H-J) . These results, along with those reported by others (32) , indicate that activation of the Met/ Gab1 pathway is an important driver of EMT in human HCC cells.
CCGs Function in Multiple Pathways Important for EMT. We next used KEGG pathway analysis to determine whether any signaling pathways or cellular processes are enriched among the CCGs identified in tumors. Strikingly, multiple pathways and cellular processes known to be involved in EMT, including Wnt signaling, adherens junctions, focal adhesion, Notch signaling, MAPK signaling, regulation of actin cytoskeleton, and TGFβ signaling (5), were enriched among the CCGs identified in tumors (Fig.  5A) , further supporting the hypothesis that transposon mutagenesis plays an important role in driving EMT and inducing a mesenchymal phenotype in IHBC/SB-derived tumors.
Ubiquitin-mediated proteolysis was the most enriched pathway in tumors with 26 CCGs functioning in this process. Whereas ubiquitin-mediated proteolysis is not commonly associated with EMT, all IHBC/SB-derived tumors had one or more mutations in a CCG that functions in this process (Fig. 5B) . Interestingly, these 26 CCGs also appear to be clinically relevant in human HCC. TCGA data show that deregulation of these CCGs in human HCC was significantly correlated with poor patient survival (Fig. S4 ).
Ubiquitin-Mediated Proteolysis Is Linked to EMT in Human HCC Cells.
To determine whether ubiquitin-mediated proteolysis is linked to EMT in human HCC, we focused on the HECT, UBA, and WWE domain containing 1 (Huwe1) gene, the most frequently mutated gene linked to ubiquitin-mediated proteolysis in tumors (Fig. 5B) . Transposon insertions in Huwe1 are scattered throughout the gene (Fig. 5C) , and its expression is significantly down-regulated in tumors with insertions in Huwe1 (Fig. 5D ), suggesting that Huwe1 is a tumor suppressor gene. Therefore, we investigated whether HUWE1 knockdown effects EMT in human HCC cells.
Knockdown of HUWE1 using two different siRNAs increased the expression of mesenchymal markers CDH2 (cadherin 2, type 1, Ncadherin), FN, and VIM (Fig. 5E ) and the EMT-TFs SNAI1 and ZEB1 (Fig. 5E ). HUWE1 knockdown also enhanced the migration of cells from three human HCC cell lines (Fig. 5 F-H) , suggesting that HUWE1 is an EMT suppressor in human HCC. Importantly, we also found a significant negative correlation between the expression of HUWE1 and poor prognosis in patients with HCC, indicating that HUWE1 also has clinical relevance in human HCC (Fig. 5I ).
Protein-Tyrosine Phosphatase, Nonreceptor-Type 12 and Kdm6a Also Regulate EMT in Human HCC Cells. We also asked whether two other SB-identified trunk drivers, protein-tyrosine phosphatase, Ubiquitin nonreceptor-type 12 (Ptpn12) and Kdm6a, regulate EMT in human HCC cells. We chose these genes because they had the highest average read counts of all trunk drivers identified in tumors (Fig. 3C) . Similar to Huwe1, transposon insertions in both genes were located throughout the coding region ( Fig. 6 A and B) , and their expression was significantly down-regulated in tumors with SB insertions (Fig. 6  C and D) , suggesting they are tumor suppressor genes as well.
Knockdown of these genes using two independent siRNAs in human HCC cells once again led to the up-regulation of mesenchymal markers CDH2, FN, and VIM and the EMT-TFs TWIST1 and ZEB1 (Fig. 6 E and F) . Down-regulation of these genes also significantly increased the migration of cells from two human HCC cell lines, SNU-387 and SNU-475 (Fig. 6 G-J) , further confirming that these genes are suppressors of EMT in human HCC cells. Combined with our previous studies, all five of the top trunk drivers identified in IHBC/SB-derived tumors are confirmed drivers of EMT in human HCC cells.
SB-Identified EMT Regulators Promote Sorafenib Resistance in Human
HCC Cells. Two recent reports have shown that EMT promotes chemoresistance of tumor cells (12, 13) . To determine whether EMT contributes to chemoresistance in human HCC cells, we examined the ability of three SB-identified EMT suppressorsKdm6a, Huwe1, and Ptpn12-to modify the chemosensitivity of HCC cells. We knocked down the expression of each of these genes in human HCC cells using siRNA and then treated the cells with sorafenib, the sole potentially effective antineoplastic agent against HCC identified to date (4). Intriguingly, on sorafenib treatment, the viability of HCC cells containing siRNAs targeting these genes was significantly higher than that of cells receiving negative control siRNA (Fig. 7 A-C) . Thus, EMT also seems to confer chemoresistance to human HCC cells.
Finally, to study the potential mechanism of EMT-induced sorafenib resistance, we assessed the proliferation and apoptosis of HCC cells on knockdown of these three EMT suppressors. Knockdown of these genes significantly reduced HCC cell proliferation (Fig. 7 D-F) , and HCC cells with siRNAs targeting these genes significantly attenuated the apoptosis induced by sorafenib treatment (Fig. 7 G-I) . These findings suggest that EMT confers sorafenib resistance to human HCC cells through reduced cell proliferation and increased apoptotic tolerance.
Discussion
In this study, we have shown that mobilization of SB transposons in immortalized mouse hepatoblasts induces mesenchymal liver tumors following transplantation into nude mice. The tumors have reduced gene expression of epithelial markers and increased expression of mesenchymal markers and EMT-TFs such as Snail, Twist1, and Zeb1. Sequencing of transposon insertion sites from 52 tumors identified 233 CCGs that are enriched for genes and cellular processes driving EMT, whereas trunk driver analysis identified 23 CCGs that appear to function early in tumorigenesis and whose mutation or alteration in patients with HCC correlates with poor survival of these patients. Validation studies have shown that deregulation of the most highly mutated CCGs in human HCC activates an EMT program that enhances cell migration and also confers sorafenib resistance to HCC cells. Thus, transposon mutagenesis appears to provide an excellent resource for identifying genes driving EMT in human HCC and for potentially identifying new drug targets for HCC.
Strikingly, Met and its binding partner Gab1 were the first and third most significantly mutated trunk drivers identified in tumors. Activating insertional mutations in Met and/or Gab1 were identified in >75% of tumors and showed very high sequencing read counts, suggesting that activation of this signaling pathway is a major driver of these tumors. This pathway has been extensively studied in various cancers and shown to be a potent oncogenic pathway involved in cancer formation, progression, and metastasis (32, 40, 41) . This pathway is activated in human HCC mainly through copy number alterations (42) , and its overexpression has been correlated with an increased incidence of intrahepatic metastases and poor prognosis in patients with HCC (43) . In HCC, HGF stimulation has been shown to activate an EMT program and to enhance the migration capacity of PLC/PRF/5 and HepG2 human liver cancer cells (21) . In the present study, we have shown that activation of the Met/Gab1 pathway by HGF treatment decreases the expression of epithelial markers and increases the migration capacity of SNU-423, SNU-449, and SNU-475 human liver cancer cells, confirming that this pathway is an important activator of EMT in HCC. These data suggest that the Met pathway could be a promising therapeutic target in HCC. Indeed, tivantinib, a selective Met inhibitor, has recently been shown to significantly improve the overall survival of Met-positive HCC patients who experienced failure of or intolerance to previous systemic therapy (44) . Phase III trials of several MET inhibitors in patients with HCC are currently underway, but the results of these trials have not yet been reported. Pathway analysis revealed that 26 CCGs identified in mesenchymal tumors function in ubiquitin-mediated proteolysis. Huwe1 was the most frequently mutated CCG and was inactivated by SB insertions in more than 70% of tumors. Huwe1 is a proven tumor suppressor gene that acts via the degradation of c-Myc/Miz1 in skin cancer (45) or Mcl-1 in HCC (46); however, a role of Huwe1 in EMT has not yet been described. In this study, we found that siRNA-mediated knockdown of Huwe1 led to increased expression of a variety of mesenchymal markers as well as EMT-TFs SNAI1 and ZEB1, leading to enhanced migration and sorafenib resistance of multiple HCC cell lines, demonstrating a new role for Huwe1 as an EMT suppressor. We also showed that down-regulation of Huwe1 is correlated with poor prognosis in patients with HCC, suggesting that inactivation of HUWE1 may contribute to the progression of HCC through activation of EMT.
The second most frequently mutated CCG that functions in ubiquitin-mediated proteolysis was Fbxw7, which was mutated in 35% of tumors. Fbxw7 is highly mutated in various human cancers and functions as a tumor suppressor through degradation of several growth promoters, including c-Myc, m-TOR, cyclin E, and c-Jun (47) . FBXW7 is also a known EMT suppressor and contributes to chemosensitivity in human HCC (48) . In IHBC/SB-derived tumors, insertions in Fbxw7 are scattered throughout the coding regions, where they are predicted to inactivate Fbxw7 expression and potentially activate EMT in IHBC/SB-derived tumors.
We also have shown that two other SB-identified trunk drivers, Ptpn12 and Kdm6a, regulate EMT in human HCC cells. PTPN12 tyrosine phosphatase was originally identified in a genetic screen for tumor suppressors in triple-negative breast cancers, where it inhibits multiple oncogenic tyrosine kinases, including HER2 and EGFR (49) . In addition, studies of Ptpn12-deficient mice have shown that Ptpn12 regulates the migration of endothelial cells, dendritic cells, and macrophages, probably through dephosphorylation of Prk2, FAK, Cas, and paxillin (50) (51) (52) . These antimigratory functions of PTPN12 also have been observed in several types of human cancers, including breast, ovary, and prostate cancers (53) (54) (55) . Consistent with this, Ptpn12 was inactivated in our IHBC/SB-derived tumors by transposon insertion. We also showed that knockdown of PTPN12 significantly increased the migration capacity and expression of mesenchymal markers and EMT-TFs in multiple human HCC cell lines, indicating that PTPN12 is a universal EMT suppressor in cancer cells as well as in normal tissues. Decreased expression of PTPN12 is also negatively correlated with tumor recurrence and survival of HCC patients (56) , further supporting the importance of this tumor suppressor in HCC. Interestingly, Ptpn12-deficient mouse embryos exhibited a failure of liver development, leading to lethality (57) , suggesting that Ptpn12 may play a fundamental role in liver development as well.
Kdm6a is an H3K27me3 demethylase that can reverse histone lysine methylation induced by Ezh2, a member of the polycomb repressive complex 2 (58). Loss-of-function mutations of KDM6A are frequently observed in various human cancers, including bladder cancers, medulloblastomas, and renal cancers (59) , suggesting that KDM6A functions as a tumor suppressor. The role of Kdm6a in cancer progression remains controversial, however. Choi et al. (36) reported that Kdm6a represses EMT genes and inhibits EMTinduced cancer stemness properties in breast cancer. Similarly, van den Beucken et al. (37) showed that hypoxia inhibits KDM6A and induces the hypermethylation of DICER, leading to the up-regulation of ZEB1 expression and promotion of EMT and cancer stemness. In contrast, Thieme et al. (58) showed that Kdm6a positively regulates the migration of hematopoietic stem cells. In addition, Kim et al. (60) reported that knockdown of KDM6A decreased the migration and invasion capacity of breast cancer cell lines.
In the present study, Kdm6a was inactivated in IHBC/SBderived tumors by transposon insertions. Knockdown of Kdm6a accelerated the migration of cells from two human HCC cell lines and increased ZEB1 expression. Because histone lysine demethylase can potentially regulate the activation of hundreds of genes, its function may vary and may depend on cell context, which could possibly generate contradictory findings.
Why IHBC/SB lines preferentially generate mesenchymal tumors following transplantation into nude mice remains unclear. One possibility is that IHBC/SB lines acquire mesenchymal properties during growth in culture, and the tumors simply reflect this preselection. Our qPCR EMT array results suggest that this is not the case, however, and instead indicate that the mesenchymal properties of tumors are acquired during growth in vivo. Consistent with this, there was almost no overlap between the CCGs detected in IHBC/SB lines and those detected in IHBC/SB-derived tumors, indicating that these EMT-related cancer genes were selectively mutated during growth in vivo. Another possible explanation is that the subcutaneous microenvironment provided selective pressure for the generation of mesenchymal tumors. This also does not appear to be the case, however, given that IHBC/SB-derived tumors generated after orthotopic injection into the liver were identical to the tumors generated after s.c. injection. EMT is linked to various fundamental processes in cancer development and progression, including migration, invasion, cancer stemness, and DNA repair (5, 6, 8, 61) , and it is possible that transposon-induced activation of an EMT program was selected during growth of IHBC/SB cells in vivo because it gave the cells a strong survival advantage. Although these tumors originated from epithelial cells and acquired many mesenchymal properties, some of our findings were not consistent with typical EMT. For instance, whereas the expressions of many known EMT markers and EMT regulators were up-regulated in tumors, including extracellular matrix proteins, TGF-β family proteins, and EMT-TFs, the expression levels of β-catenin and N-cadherin were low in these tumors. Moreover, these tumors still maintained immunopositivity for epithelial markers as well as mesenchymal markers. Therefore, the phenotype that these tumors acquired was not complete EMT in a strict sense, which requires a complete transition, but rather incomplete EMT caused by epithelial plasticity of cancer cells, which is often a transient and reversible process. This important feature of cancer cells may contribute to metastasis, cancer stemness, and drug resistance; thus, our transposon screen provides important global insights into the genes regulating this process.
In summary, our unique cell-based SB transposon screen provides, to our knowledge, the first high-throughput approach to identifying and validating genes driving EMT in human HCC. CCGs identified in this screen provide an important new resource for further studying the genes and cellular processes driving EMT in human HCC, as well as new potential therapeutic targets. Mice heterozygous for the Alb-Cre transgene were crossed to mice homozygous for Rosa26-lsl-SB11 and T2/Onc2 (6070) to generate Alb-Cre/+;T2Onc2/+;Rosa26-lsl-SB11/+ embryos used for hepatoblast isolation. For qPCR analysis, well-differentiated HCCs were collected from Alb-Cre/+;T2Onc2/+;Rosa26-lsl-SB11/+;Pten flox/flox mice and confirmed histologically by a pathologist.
Isolation and Immortalization of Embryonic Hepatoblasts. Immortalized hepatoblasts were obtained using the method reported by Strick-Marchand H et al. (26) . In brief, Alb-Cre/+;T2Onc2/+;Rosa26-lsl-SB11/+ embryos were dissected at E13.5, and dissociated cells from embryonic livers were plated into type I collagen-treated dishes. Cells were cultured in vitro with DMEM/F12 medium containing 10% FCS, penicillin-streptomycin, 50 ng/mL EGF (Gibco), 30 ng/mL IGF-II (Peprotech), and 10 μg/mL insulin (Thermo Fisher Scientific). Spontaneously immortalized hepatoblast colonies were inoculated and further cultured to obtain immortalized IHBC/SB lines. Soon after the immortalized lines were established, they were cryopreserved for transplantation. Transposons in these lines are continuously transposing during in vitro culture as well as after transplantation, because of constitutive activity of the SB11 transposase.
Embryos from C57BL6/J mice were used to establish IHBC/WT lines as a control.
In Vitro Hepatocyte Differentiation of Hepatoblasts. To induce hepatocyte differentiation in vitro, IHBC/SB lines were cultured for 14 d in medium supplemented with 20 ng/mL recombinant mouse HGF (Peprotech), 20 ng/mL recombinant mouse oncostatin M (R&D Systems), 10 −6 M dexamethazone (Sigma-Aldrich), and insulin-transferrin-selenium (Thermo Fisher Scientific) (27) . Sequencing of Transposon Insertion Sites. Transposon insertion sites were sequenced using splinkerette PCR to produce barcoded PCR products, which were then pooled and sequenced (22) (23) (24) . To obtain the maximum amount of sequencing reads and avoid PCR bias (29), we used Illumina sequencing and acoustic shearing of genomic DNA (gDNA). gDNA (3 μg per sample) was acoustically sheared to 300-bp fragments using a Covaris S220 Focusedultrasonicator and end-repaired using a Fast DNA End Repair Kit (Thermo Fisher Scientific). Adapters (linker+: 5′-GTA ATA CGA CTC ACT ATA GGG CTC CGC TTA AGG GAC-3′; linker−: 5′-phos-GTC CCT TAA GCG GAG-C3spacer-3′) were then annealed and ligated to repaired DNA. Purified DNA was PCRamplified using linker (5′-GTA ATA CGA CTC ACT ATA GGG C-3′), IRR (5′-GGA TTA AAT GTC AGG AAT TGT GAA AA-3′), and IRL (5′-AAA TTT GTG GAG TAG TTG AAA AAC GA-3′) primers. Nested secondary PCR was performed using indexed SB-2ndR primer [5′-CAA GCA GAA GAC GGC ATA CGA GAT ( DNA fragments of 300-400 bp from amplicon libraries were excised from the agarose gel and quantified using a Qubit fluorometer (Thermo Fisher Scientific), an Agilent 2100 bioanalyzer, and real-time qPCR. Excised libraries were then pooled, loaded onto two flow cell lanes, and sequenced using an Illumina Hi Seq2500 sequencer at Eurofins Genomics. Sequencing reads were converted to FASTQ format and demultiplexed using bcl2fastq-1.8.4 (Illumina) at Eurofins Genomics.
To reduce bleed-through across samples in the same flow cell, a custom dual-indexing routine was incorporated. This checked that a dual index sequence near the beginning of a read matched the barcode associated with the read, and then stripped away the index and the preceding sequence.
After these preprocessing steps, reads to the mouse genome were mapped using a modified form of our SBCapSeq pipeline. The likelihood of local hopping of the SB transposon is increased on the chromosome where the transposon concatamer is located (62) ; thus, all insertions on chromosome 4, the site of the T2/Onc2 donor concatamer, were removed from the dataset before subsequent analysis, unless indicated otherwise. Sfi1 is listed as a singlecopy gene in the reference mouse genome; however, it is estimated that the mouse genome has 20-30 copies of Sfi1 (63) . Insertions in multiple different Sfi1 loci are erroneously annotated to a single Sfi1 gene located on chromosome 11; thus, we removed Sfi1 from our lists of CIS genes, because this is a known artifact. We reported the resulting TA sites and their read depths in BED format. A total of 871,231 and 6,541,525 mapped reads, corresponding to 50,215 and 118,530 nonredundant insertion sites, were identified from seven IHBC/SB lines and 52 IHBC/SB-derived tumors, respectively (Datasets S1 and S2).
CCGs were identified using gCIS (30) , which looks for a higher density of transposon insertions within the coding regions of all RefSeq genes than would be predicted by chance. gCIS analysis was performed using insertions with >10 sequence read counts. Genes with a P value <0.05, as calculated by the χsiRNA Transfection. siRNA oligonucleotides targeting candidate tumor suppressor genes and nontargeting siRNA oligonucleotides (negative control) were purchased from Thermo Fisher Scientific. A list of siRNA oligonucleotides is provided in Table  S3 . siRNA transfection was performed using Lipofectamine RNAiMAX transfection reagent (Thermo Fisher Scientific) according to the manufacturer's instructions. Knockdown efficiency was determined by qRT-PCR at 2-3 d after transfection.
Scratch Assay. Scratch assays were performed according to a published protocol (39) . In brief, 2.0-4.0 × 10 5 cells were seeded into six-well plates. Once the cells became subconfluent, the cell monolayer was scraped in a straight line using a p500 pipet tip. The cells were then washed once, the medium replaced with complete medium, and a first image of the scratch was acquired. After a 24-h incubation, a second image was acquired, and the area of cell migration was quantitated using ImageJ software.
WST-1 Cell Proliferation aAsay. WST-1 assays were performed using the Premix WST-1 cell proliferation assay system (Takara Bio) according to the manufacturer's protocol. In brief, 3-4 × 10 3 cells were seeded into 96-well plates and cultured with medium containing 1-10% (vol/vol) FBS for 1-5 d. WST-1 regent was then added to each well, followed by incubattion at 37°C for 1.5 h. The absorbance at 450 nm and 650 nm (reference) was then measured using an Infinite 200 PRO multimode reader (Tecan).
Casapase-3/7 Assays. Caspase-3 and -7 activity of cell supernatant was measured using the Caspase-Glo 3/7 assay (Promega) according to the manufacturer's instructions.
qRT-PCR. Total RNA was extracted from cells using the RNeasy Plus Mini Kit (Qiagen). Reverse transcription was carried out using SuperScript VILO Master Mix (Thermo Fisher Scientific). qPCR was performed using the QuantStudio 12K Flex Real-Time PCR system with TaqMan Gene Expression Assay probes (Thermo Fisher Scientific). A list of TaqMan probes is provided in Table S3 .
For the EMT PCR array, reverse transcription was carried out using a RT 2 First Strand Kit (Qiagen). qPCR was performed using the QuantStudio 12K Flex Real-Time PCR system and RT 2 Profiler PCR EMT mouse arrays (Qiagen), according to the manufacturer's instructions.
Western Blot Analysis. Cells were lysed in RIPA buffer (Pierce) with a protease and phosphatase inhibitor mixture (Pierce) on ice. The cell lysates were cleared by centrifugation at 10,000 × g for 15 min at 4°C. The protein concentrations were determined using a bicinchoninic acid protein assay kit (Pierce). The protein lysates were electrophoretically separated with SDS polyacrylamide gels and then transferred onto a polyvinylidene fluoride membrane. Immunodetection was performed using the following antibodies: anti-phospho-Met (Tyr1234), anti-Met, anti-phospho-Gab1 (Tyr307), anti-Gab1, and anti-β-actin (Cell Signaling Technology). Detection of immunolabeled proteins was performed using a chemiluminescent substrate (Thermo Fisher Scientific).
Transposon Excision Assay. Mobilization of SB transposons was assayed as described previously (25) . The following primers were used for excision PCR: 5′-TGT GCT GCA AGG CGA TTA-3′ and 5′-ACC ATG ATT ACG CCA AGC-3′. THE PCR generates a 2.2-kb product if no transposon is mobilized from the concatamer. If transposition mobilization occurs, a 225-bp product is generated.
Immunohistochemistry. Allograft tumor sections were deparaffinized, rehydrated, and stained with H&E, mouse monoclonal antiKi-67 (BD Biosciences), mouse monoclonal anti-SB transposase (R&D Systems), mouse monoclonal anti-Vimentin (Abcam), mouse monoclonal anti-Pan-CK (Abcam), and mouse monoclonal anti-EpCAM (Millipore) antibodies. The Dako Animal Research Kit (Dako) was used for mouse primary antibodies. DAB was used for visualization, and counterstaining was performed with hematoxylin.
Bioinformatic Analysis. Mouse CISs were converted to human genes using two different annotation databases, MGI EntrezGene associations (www.informatics.jax.org/) and HGNC complete annotations (www.genenames.org/). Mouse genetic markers were downloaded from MGI (www.informatics.jax.org/tools. shtml). The gene catalog registered in The Cancer Gene Census was downloaded from COSMIC (cancer.sanger.ac.uk/census/). DAVID Bioinformatics Resources version 6.7 (https://david. ncifcrf.gov/) was used for pathway analysis.
To investigate the association between gene expression and prognosis in the patients with HCC, we downloaded GSE10141 expression data and clinical information from the Gene Expression Omnibus (www.ncbi.nlm.nih.gov/geo/; ref. PMID: 18923165). We obtained the Human 6k Transcriptionally Informative Gene Panel for DASL data from 80 HCC samples and patient survival data. We used R 2.15.3 (R Development Core Team) for differential gene expression and Kaplan-Meier survival analysis.
We used cBioPortal for Cancer Genomics (www.cbioportal. org/) to analyze the correlation between genomic alterations in the 23 trunk drivers or 26 CCGs functioning in the ubiquitinmediated proteolysis pathway and survival of the HCC patients in The Cancer Genome Atlas dataset (cancergenome.nih.gov/), containing 193 HCC patients with mutation and copy number alteration. Cases are defined as "with alteration" when a copy number change (either amplification or loss) or/and nonsynonymous somatic mutation is seen in any of these genes. We used GENE-E (www.broadinstitute.org/cancer/software/GENE-E/) for hierarchical clustering analysis of the EMT qPCR array.
Statistics. All data are provided as mean ± SD. Statistical analyses were performed using an unpaired Student's t test, MannWhitney U test, one-way ANOVA, or Kruskal-Wallis test followed by Dunnett's multiple-comparisons test using GraphPad Prism 6 version 6.0f. P < 0.05 was considered statistically significant. p = 0.24 by Log-Rank test Fig. S1 . Immortalization rates of hepatoblasts obtained from Alb-Cre/+;T2Onc2/+;Rosa26-lsl-SB11/+ (SB) and C57BL6/J (WT) mice. P values were calculated using the log-rank test.
Liver
IHBC/SB-derived tumor A TCGA dataset containing 193 HCC patients with mutation and/or copy number data, in addition to patient survival information, was used for this analysis. Statistical analysis was performed with the log-rank test using cBioPortal. 
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